6-溴吲唑-3-羧酸 | 660823-36-9

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 6-溴吲唑-3-羧酸
• 中文别名: 6-溴吲唑-3-甲酸
• 英文名称: 6-bromo-1H-indazole-3-carboxylic acid
• CAS: 660823-36-9
• 化学式: C₈H₅BrN₂O₂
• 分子量: 241.044
• InChiKey: QDQJIDDXPACPKY-UHFFFAOYSA-N

物化性质

• 沸点：
  493.4±25.0 °C(Predicted)
• 密度：
  1.946±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8℃，请保持干燥并密封。

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  6-溴-1H-吲唑-3-甲酸甲酯	methyl 6-bromo-1H-indazole-3-carboxylate	885278-42-2	C9H7BrN2O2	255.071

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  6-溴-1H-吲唑-3-甲酸甲酯	methyl 6-bromo-1H-indazole-3-carboxylate	885278-42-2	C9H7BrN2O2	255.071
  6-溴-1H-咪唑-3-羧酸乙酯	ethyl 6-bromo-1H-indazole-3-carboxylate	885272-94-6	C10H9BrN2O2	269.098
  ——	tert-butyl 6-bromo-indazole-3-carboxylate	865887-15-6	C12H13BrN2O2	297.151
  6-溴-1-甲基吲唑-3-甲酸甲酯	methyl 6-bromo-1-methyl-1H-indazole-3-carboxylate	946427-77-6	C10H9BrN2O2	269.098
  ——	6-bromo-1-(2-trimethylsilanylethoxymethyl)-1H-indazole-3-carboxylic acid	1044941-24-3	C14H19BrN2O3Si	371.306
  ——	ethyl 6-(4-aminophenyl)-1H-indazole-3-carboxylate	1228450-05-2	C16H15N3O2	281.314
  ——	6-bromo-1-(2-trimethylsilanylethoxymethyl)-1H-indazole-3-carboxylic acid methyl ester	1422982-26-0	C15H21BrN2O3Si	385.333
  ——	6-bromo-1H-indazole-3-carboxylic acid (4-fluorophenyl)amide	660823-03-0	C14H9BrFN3O	334.147
  ——	1-tert-butyl 3-ethyl 6-bromo-1H-indazole-1,3-dicarboxylate	1228451-59-9	C15H17BrN2O4	369.215
  ——	ethyl 6-(4-(3-(3,4-dichlorophenyl)ureido)phenyl)-1H-indazole-3-carboxylate	1228450-38-1	C23H18Cl2N4O3	469.327

反应信息

• 作为反应物：
  描述：

  6-溴吲唑-3-羧酸 在 氯化亚砜 作用下， 反应 1.5h， 生成 6-bromo-1H-indazole-3-carbonyl chloride
  参考文献：
  名称：

  从零碎到领先：从头设计和开发选择性 FGFR2 抑制剂

  摘要：

  成纤维细胞生长因子受体 (FGFR) 与一系列癌症有关，目前正在临床试验中评估几种泛激酶和选择性 FGFR 抑制剂。Pan-FGFR 抑制剂通常会引起毒副作用，并且很少有亚型选择性抑制剂的例子。在此，我们描述了一种结构导向的方法来开发选择性 FGFR2 抑制剂。对现有片段系列进行了从头设计，以产生预计可提高抗 FGFR 效力的化合物。随后的几轮迭代合成和生物学评估产生了一种具有纳摩尔效力的抑制剂，该抑制剂对 FGFR2 的选择性优于对 FGFR1/3 的选择性。先导抑制剂的细微变化导致对 FGFR2 的选择性完全丧失。X 射线晶体学研究揭示了 P 环中抑制剂特异性的形态差异，这被认为是这些化合物选择性的基础。其他对接研究预测了 FGFR2 选择性 H 键，可用于设计更具选择性的 FGFR2 抑制剂。

  DOI：

  10.1021/acs.jmedchem.1c01163
• 作为产物：
  描述：

  2-(4-溴苯基)-2-氧代乙酸 在 盐酸 、 sodium nitrite 、 tin(II) chloride dihdyrate 作用下， 以 水 为溶剂， 反应 2.0h， 生成 6-溴吲唑-3-羧酸
  参考文献：
  名称：

  Design and synthesis of 1H-indazole-3-carboxamide derivatives as potent and selective PAK1 inhibitors with anti-tumour migration and invasion activities

  摘要：

  Aberrant activation of p21-activated kinase 1 (PAK1) is associated with tumour progression, and PAK1 has been recognized as a promising target for anticancer drug discovery. However, the development of potent PAK1 inhibitors with satisfactory kinase selectivity and favourable physicochemical properties remains a daunting challenge. Herein, we identified the 1H-indazole-3-carboxamide derivatives as potential PAK1 inhibitors using a fragment-based screening approach. The representative compound 301 exhibited excellent enzyme inhibition (PAK1 IC50 = 9.8 nM) and high PAK1 selectivity toward a panel of 29 kinases. The Structure-activity relationship (SAR) analysis showed that substituting of an appropriate hydrophobic ring in the deep back pocket and introducing a hydrophilic group in the bulk solvent region were critical for PAK1 inhibitory activity and selectivity. Additionally, the hERG channel activity of 301 demonstrated its low risk of hERG toxicity. Furthermore, it significantly suppressed the migration and invasion of MDA-MB-231 cells by downregulating Snail expression without affecting the tumour growth. These results provide a new type of chemical scaffolds targeting PAK1 and suggested that 1H-indazole-3-carboxamide derivatives may serve as lead compounds for the development of potential and selective PAK1 inhibitors. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112517

文献信息

• Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor
  作者：Jonathan E. Wilson、Gaurav Patel、Chirag Patel、Francois Brucelle、Annissa Huhn、Anna S. Gardberg、Florence Poy、Nico Cantone、Archana Bommi-Reddy、Robert J. Sims、Richard T. Cummings、Julian R. Levell

  DOI：10.1021/acsmedchemlett.0c00155

  日期：2020.6.11

  inflammatory disorders, and neurodegeneration. A novel, highly potent, orally bioavailable EP300/CBP histone acetyltransferase (HAT) inhibitor, CPI-1612 or 17, was developed from the lead compound 3. Replacement of the indole scaffold of 3 with the aminopyridine scaffold of 17 led to improvements in potency, solubility, and bioavailability. These characteristics resulted in a 20-fold lower efficacious

  组蛋白乙酰基转移酶，CREB结合蛋白（CBP）和EP300是主要的转录共调节剂，与多种疾病有关，例如癌症，炎症性疾病和神经变性。从铅化合物3开发了一种新型的高效口服生物利用EP300 / CBP组蛋白乙酰转移酶（HAT）抑制剂CPI-1612或17。用17的氨基吡啶支架替换3的吲哚支架导致效力，溶解度和生物利用度的提高。在JEKO-1肿瘤小鼠异种移植研究中，这些特性导致17的有效剂量相对于铅3降低了20倍。
• [EN] SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK<br/>[FR] SALICYLAMIDES DE SPIROHEPTANE ET COMPOSÉS ASSOCIÉS UTILISÉS COMME INHIBITEURS DE ROCK
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017123860A1

  公开（公告）日：2017-07-20

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式(I)的化合物：或立体异构体、互变异构体或药用可接受的盐，其中所有变量如本文所述定义。这些化合物是选择性的ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用同一化合物治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
• 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR
  申请人：Staben Steven

  公开号：US20120214762A1

  公开（公告）日：2012-08-23

  The invention relates to novel compounds of Formula I: wherein A, Y, R 1 , R 2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

  这项发明涉及公式I的新化合物： 其中A、Y、R1、R2和下标b各自具有如本文所述的含义，以及公式I的化合物、立体异构体、几何异构体、互变异构体、溶剂合物、代谢物、同位素、药学上可接受的盐或其前药。公式I的化合物及其药物组成物在治疗观察到NF-kB信号通路的不良或过度激活的疾病和紊乱中是有用的。
• INHIBITING FATTY ACID SYNTHASE (FASN)
  申请人：Forma Therapeutics, Inc.

  公开号：EP3636637A1

  公开（公告）日：2020-04-15

  The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.

  本公开涉及FASN的抑制剂。这些化合物可用于治疗与FASN抑制相关的疾病或疾病。例如，本公开涉及用于抑制FASN的化合物和组合物，治疗、预防或改善与FASN抑制相关的疾病或疾病的方法，以及这些化合物的合成方法。
• [EN] BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF<br/>[FR] COMPOSÉS BENZOPYRAZOLE ET ANALOGUES DE CEUX-CI
  申请人：BIOCRYST PHARM INC

  公开号：WO2017136395A1

  公开（公告）日：2017-08-10

  Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula (I), and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity.

  揭示了式（I）的化合物及其药学上可接受的盐。这些化合物是裂解系统的抑制剂。还提供了包含式（I）化合物的药物组合物，以及涉及使用这些化合物和组合物在治疗和预防由异常裂解系统活性特征的疾病和状况中的方法。